Market Place
Sourcing Support
Enforcement Report - Week of August 23, 2023
23 Aug 2023 //
FDA
5 pharmas lambasted by UK watchdog for marketing snafus
01 Aug 2022 //
FIERCEPHARMA
Advanced Accelerator Applications USA is on Health Canada Inspection List
27 Jul 2022 //
HEALTH CANADA
Enforcement Report - Week of April 13, 2022
13 Apr 2022 //
FDA
Crinetics spins out radiopharma efforts into a new company
19 Oct 2021 //
ENDPTS
Novartis backs up Endocyte buyout with prostate cancer data
04 Jun 2021 //
FIERCE BIOTECH
Novartis says radioligand therapy improves prostate cancer survival
23 Mar 2021 //
REUTERS
Bain`s Orly Mishan joins Pfizer`s neuro spinout Cerevel
17 Aug 2019 //
ENDPTS
Chimerix now can’t even recruit patients for their trials
09 May 2019 //
ENDPTS
Novartis aims for 10 blockbuster launches by 2020
30 Jan 2019 //
PMLIVE
Endocyte goes from nosedive to Novartis’ latest acquisition
27 Dec 2018 //
STAT NEWS
Monteverde Class Action Lawsuit On Behalf Of Shareholders Of Endocyte
16 Nov 2018 //
PR NEWSWIRE
With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A
16 Nov 2018 //
ENDPTS
AstraZeneca digs deeper into cancer with Innate stake
23 Oct 2018 //
REUTERS
Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong
19 Oct 2018 //
STAT NEWS
Endocyte’s little deal a year ago comeback capped by $2.1B Novartis buyout
18 Oct 2018 //
ENDPTS
With Clear Regulatory Path, Endocyte Raises $175M
12 Sep 2018 //
BIOCENTURY
Endocyte & ITM Announce Long-Term Supply Agreement No-Carrier-Added Lutetium-177
09 Jul 2018 //
PRESS RELEASE
Image Following Treatment with 177Lu-PSMA-617 Selected by Nuclear Medicine
26 Jun 2018 //
PRESS RELEASE
Endocyte to Join the Russell 3000® Index
25 Jun 2018 //
PRESS RELEASE
Endocyte Announces Presentations on PSMA-617 at the 2018 Society
22 Jun 2018 //
PRESS RELEASE
Endocyte Announces Enrollment of 1st Patient Ph3 VISION Trial of 177Lu-PSMA-617
05 Jun 2018 //
PRESS RELEASE
Endocyte to Present at Jefferies Healthcare Conference
29 May 2018 //
PRESS RELEASE
Endocyte Announces Presentation of Ph2 Data from Investigator 177Lu-PSMA-617
16 May 2018 //
PRESS RELEASE
Endocyte Announces Pricing of Public Offering of Common Stock
28 Feb 2018 //
PRESS RELEASE
Endocyte& ITM Announce Supply Agreement No-Carrier-Added Lutetium for the Ph3
26 Feb 2018 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.